Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 21:M22-3350. doi: 10.7326/M22-3350

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

This article is made available via the PMC Open Access Subset for unrestricted re-use for research, analyses, and text and data mining through PubMed Central. Acknowledgement of the original source shall include a notice similar to the following: "© 2020 American College of Physicians. Some rights reserved. This work permits non-commercial use, distribution, and reproduction in any medium, provided the original author and source are credited." These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.

PMC Copyright notice

Figure 2. Primary composite efficacy end point within 90 days. Kaplan–Meier curves of the primary composite efficacy end point within 90 d for participants randomly assigned to apixaban versus placebo (inset shows 30-d event curves). The 95% CIs are shown in the inset. — Kaplan–Meier curves of the primary composite efficacy end point within 90 d for participants randomly assigned to apixaban versus placebo (inset shows 30-d event curves). The 95% CIs are shown in the inset.